Quotient Sciences Translational Pharmaceuticals Quotient Sciences Translational Pharmaceuticals

X

Digital content for Sanofi

  • Webinars & Exhibitions

PharmaCompass

https://www.globenewswire.com//news-release/2023/09/25/2748334/0/en/Press-Release-Once-weekly-ALTUVIIIO-approved-in-Japan-as-a-new-class-of-factor-VIII-therapy-for-hemophilia-A.html

GLOBENEWSWIRE
25 Sep 2023

https://www.globenewswire.com//news-release/2023/09/22/2747747/0/en/Press-Release-Availability-of-the-Q3-2023-Memorandum-for-modelling-purposes.html

GLOBENEWSWIRE
22 Sep 2023

https://www.fiercepharma.com/pharma/sanofi-steadfast-slimming-down-offloads-11-central-nervous-system-meds-pharmanovia

Zoey Becker FIERCE PHARMA
19 Sep 2023

https://www.globenewswire.com//news-release/2023/09/19/2745307/0/en/Press-Release-Sanofi-supporting-vulnerable-communities-as-part-of-commitment-to-social-impact-and-fight-against-climate-change.html

GLOBENEWSWIRE
19 Sep 2023

https://www.businesswire.com/news/home/20230918003077/en

BUSINESSWIRE
18 Sep 2023

https://www.globenewswire.com//news-release/2023/09/14/2743056/0/en/First-Wave-BioPharma-Announces-Exclusive-Global-License-Agreement-for-Capeserod-from-Sanofi.html

GLOBENEWSWIRE
14 Sep 2023

https://www.globenewswire.com//news-release/2023/09/11/2741125/0/en/Sanofi-Information-concerning-the-total-number-of-voting-rights-and-shares-August-2023.html

GLOBENEWSWIRE
11 Sep 2023

https://www.sanofi.com/en/media-room/press-releases/2023/2023-09-05-14-35-45-2737579

PRESS RELEASE
05 Sep 2023

https://www.reuters.com/business/healthcare-pharmaceuticals/us-senators-push-drugmakers-details-low-cost-insulin-programs-2023-08-31/

REUTERS
01 Sep 2023

https://www.biopharmadive.com/news/sanofi-houman-ashrafian-research-development-john-reed/692448/

Jacob Bell BIOPHARMADIVE
01 Sep 2023
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY